A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine
Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Oncotarget - 9(2018), 5 vom: 19. Jan., Seite 6607-6614 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yi, Jun Ho [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Revised 20.11.2019 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.23823 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281225052 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281225052 | ||
| 003 | DE-627 | ||
| 005 | 20231225031136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.23823 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0937.xml |
| 035 | |a (DE-627)NLM281225052 | ||
| 035 | |a (NLM)29464096 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yi, Jun Ho |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A multicenter, retrospective analysis of elderly patients with acute myeloid leukemia who were treated with decitabine |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.11.2019 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Decitabine is widely accepted as the treatment options for elderly acute myeloid leukemia (AML) patients. However, the efficacy has yet been assessed in Asian population. We retrospectively analyzed the outcomes of 80 Korean elderly AML patients who were treated with decitabine. The median age was 74 years (range, 64 to 86 years) and 6 (7.5%), 48 (60.0%), and 25 (31.3%) patients were categorized to favorable, intermediate, and poor risk group, respectively. The median OS was 10.2 months (95% CI 5.0-15.4). Given that decitabine treatment demonstrated improved clinical outcomes, it could be considered as one of the first-line treatment for Korean elderly AML patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a acute myeloid leukemia | |
| 650 | 4 | |a decitabine | |
| 650 | 4 | |a elderly patients | |
| 700 | 1 | |a Park, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Jung Han |e verfasserin |4 aut | |
| 700 | 1 | |a Won, Young-Woong |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Do Hyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Boram |e verfasserin |4 aut | |
| 700 | 1 | |a Uhm, Jieun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hae Su |e verfasserin |4 aut | |
| 700 | 1 | |a Jung, Chul Won |e verfasserin |4 aut | |
| 700 | 1 | |a Jang, Jun Ho |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 9(2018), 5 vom: 19. Jan., Seite 6607-6614 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:5 |g day:19 |g month:01 |g pages:6607-6614 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.23823 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 5 |b 19 |c 01 |h 6607-6614 | ||